FibroGen (FGEN) Tops Q3 EPS by 14c, Misses on Revenue; Offers FY24 Revenue Guidance

FibroGen (NASDAQ: FGEN) reported Q3 EPS of ($0.17), $0.14 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $46.3 million versus the consensus estimate of $34.84 million.

GUIDANCE:

FibroGen sees FY2024 revenue of $135-150 million, versus the consensus of $174.4 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Deutsche Bank Upgrades Huizhou Desay Sv Automotive Co (002920:CH) to Hold
• JPMorgan Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral